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BACKGROUND/OBJECTIVES: Heavy alcohol drinking is a risk factor of colorectal cancer (CRC), but little is known on the effect of
polymorphisms in the alcohol-metabolizing enzymes, alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) on the
alcohol-related risk of CRC in Caucasian populations.
SUBJECTS/METHODS: A nested case–control study (1269 cases matched to 2107controls by sex, age, study centre and date of
blood collection) was conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) to evaluate the
impact of rs1229984 (ADH1B), rs1573496 (ADH7) and rs441 (ALDH2) polymorphisms on CRC risk. Using the wild-type variant of each
polymorphism as reference category, CRC risk estimates were calculated using conditional logistic regression, with adjustment for
matching factors.
RESULTS: Individuals carrying one copy of the rs1229984(A) (ADH1B) allele (fast metabolizers) showed an average daily alcohol
intake of 4.3 g per day lower than subjects with two copies of the rs1229984(G) allele (slow metabolizers) (Pdiffo0.01). None of the
polymorphisms was associated with risk of CRC or cancers of the colon or rectum. Heavy alcohol intake was more strongly
associated with CRC risk among carriers of the rs1573496(C) allele, with odds ratio equal to 2.13 (95% conﬁdence interval: 1.26–3.59)
compared with wild-type subjects with low alcohol consumption (Pinteraction¼ 0.07).
CONCLUSIONS: The rs1229984(A) (ADH1B) allele was associated with a reduction in alcohol consumption. The rs1229984 (ADH1B),
rs1573496 (ADH7) and rs441 (ALDH2) polymorphisms were not associated with CRC risk overall in Western–European populations.
However, the relationship between alcohol and CRC risk might be modulated by the rs1573496 (ADH7) polymorphism.
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INTRODUCTION
Alcohol intake has been identiﬁed as an important risk factor for
the development of various types of cancer,1 including colorectal
cancer (CRC). Expert reviews from the International Agency for
Research on Cancer2 and the World Cancer Research Fund3
conﬁrm the involvement of alcohol in CRC aetiology. Among other
hypotheses, alcohol may affect the intestinal absorption,
hepatobiliary metabolism and renal excretion of folate4 and may
result in impaired retinol status, thus providing a more tumour-
promoting environment,5 or can promote oxidative stress.6 In
addition, although evidence from experimental animal models
indicate that alcohol by itself is not carcinogenic,2 alcohol intake
might have a role in colorectal carcinogenicity through
acetaldehyde, an oxidation product of alcohol.7,8
Acetaldehyde associated with alcoholic beverages has been
labelled as carcinogenic to humans (IARC Group 1).9 It is removed
from the blood via a second reaction catalysed by aldehyde
dehydrogenase (ALDH) enzymes, which oxidize it into acetate.10
The efﬁciency of each of these reactions depends on multiple
alcohol dehydrogenase (ADH) and ALDH enzymes, which are
encoded by different genes, and which occur in several variants.
Therefore, the risk of CRC incidence in relation to alcohol intake
could be modulated by genetic factors, as the efﬁciency in
converting ethanol to acetaldehyde, and its subsequent
conversion into acetate is largely determined by the ADH and
ALDH gene families.11–13
Although the few existing studies on CRC in Caucasian
populations have been inconclusive,14 studies in Japanese
populations showed an increased CRC risk with the ADH1B
polymorphism (slow metabolizer)15 and a signiﬁcant interaction
between the ALDH2 and ADH2 polymorphisms, which was more
apparent in low folate consumers than in high folate consumers.16
The ADH polymorphisms show sizeable heterogeneity among
ethnic groups.10 The allele rs1229984*2 (His) (rs1229984(A) in the
present study), which codes for ‘fast’ metabolism of ethanol,17 is a
frequent allele in Asian populations, while the allele rs1229984*1
(Arg) (rs1229984(G) in the present study) is a major allele in
Caucasians.18
The epidemiological investigations that have so far explored the
association between ADH and ALDH polymorphisms and risk of
CRC have been of relatively small size and very few data are
available from European populations. In light of this, a nested
case–control study was conducted within the EPIC, to investigate
whether the rs1229984 (ADH1B), rs1573496 (ADH7) and rs441
(ALDH2) polymorphisms are associated with CRC risk in European
populations, and whether these genes interact with alcohol intake
in the aetiology of CRC. In our study, differences in the
associations between single-nucleotide polymorphisms (SNPs) by
anatomical sub-sites were also evaluated.
MATERIALS AND METHODS
Subjects
EPIC is a multicentre prospective cohort study with more than 520 000
participants enrolled from 23 centres in Denmark, France, Greece,
Germany, Italy, The Netherlands, Norway, Spain, Sweden and the United
Kingdom. EPIC is designed to investigate the relation between dietary and
lifestyle/environmental factors and cancer incidence. The rationale and
methods of the EPIC study have been previously reported in detail.19
Between 1992 and 1998, standardized lifestyle questionnaires,
anthropometric data and blood samples were collected from most study
participants at recruitment, before disease onset or diagnosis. Dietary
habits, including alcohol consumption, over the previous 12 months were
assessed at recruitment by validated country-speciﬁc dietary
questionnaires designed to ensure high compliance while accounting for
geographical speciﬁcity of diet.19,20
The present study included subjects who, during an average of 7.2 years
follow-up, developed cancer of the colon (n¼ 797), speciﬁcally in the
caecum, appendix, ascending colon and hepatic ﬂexure, transverse colon,
splenic ﬂexure (proximal) (C18.0–18.5; International Statistical Classiﬁcation
of Diseases, Injury and Causes of Death, 10th Revision), descending and
sigmoid colon (distal) (C18.6–C18.7), tumours that were overlapping or
unspeciﬁed (C18.8 and C18.9), as well as cancer of the rectum (n¼ 472),
with tumours occurring at the rectosigmoid junction (C19) and rectum
(C20). CRC is deﬁned as a combination of all the colon and rectal cancer
cases. Anal canal tumours were excluded.
For each case (n¼ 1269), upto two controls (n¼ 2107) were randomly
selected by incidence density sampling among cohort members alive and
free of cancer at the time of case diagnosis, with blood samples available,
and matched by sex, age (±2.5 years), centre and date of blood collection
(±45 days). Women were further matched by menopausal status (pre-
menopausal, post-menopausal, peri-menopausal/unknown), phase of
menstrual cycle at blood collection and usage of hormone replacement
therapy at the time of blood collection (yes/no). The additional matching
criteria for women were of necessity to other EPIC nested case–control
studies that were being conducted using the same matched case–control
sets.
This study was approved by relevant Ethical Review Boards of IARC and
all EPIC centres.
SNP selection/genotyping and folate assessment
The rs1229984 (ADH1B), rs1573496 (ADH7) and rs441 (ALDH2) polymorph-
isms were chosen because investigations on Central European populations
indicate that they are associated with the risk of upper and aero-digestive
tract cancer and that the association is potentially modiﬁable by the level
of alcohol consumption.21
Genotyping for rs1229984 (ADH1B), rs1573496 (ADH7) and rs441 (ALDH2)
polymorphisms was performed by Taqman methodology in 384-well plates
read with the Sequence Detection Software on an ABI-Prism7900 instrument,
according to the manufacturer’s instructions (Applied Biosystems / Life
Technologies, Saint-Aubin, France). Primers and probes were supplied by
Applied Biosystems (Assays-by-Design). Each plate included a negative control
(no DNA). Positive controls were duplicated on a separate plate. A random
selection of the study subjects (both cases and controls) was re-genotyped
for each polymorphism to examine the reliability of the Taqman genotyping
assays. Internal duplicate concordance was 499.9% and the genotyping
success rate was at least 94%. Some subjects were excluded due to incomplete
genotyping data. Thus, the ﬁnal number of complete case–control sets
utilized was: rs1229984 (ADH1B), (number colon¼ 781; number rectal¼ 466),
rs1573496 (ADH7) (number colon¼ 761; number rectal¼ 436) and rs441
(ALDH2) (number colon¼ 762; number rectal¼ 451).
Blood folate measurements were conducted at the LOCUS for
homocysteine and related vitamins, University of Bergen (Norway) using
a Lactobacillus casei microbiological assay,22 adapted to a microtiter plate
format and carried out by a robotic workstation (Micro-lab AT plus 2;
Hamilton Bonaduz AG, Bonaluz, Switzerland).23 Blood collection and
storage procedures of the EPIC study have been previously described in
detail.24
Statistical analyses
For each polymorphism, genotype distributions in control subjects were
tested for Hardy–Weinberg equilibrium. Means and associated measures of
variation (10th and 90th percentiles) of total alcohol intake and intakes of
alcoholic beverages were calculated for cases and controls. Differences
between cases and controls in (log-transformed) total alcohol intake and
intakes of alcoholic beverages at baseline were assessed with linear
regression models adjusted by sex and country. Similarly, linear regression
models were used to compute adjusted means of total alcohol intake and
intakes of alcoholic beverages at baseline (and associated s.e.) for each
variants of the rs1229984 (ADH1B), rs1573496 (ADH7) and rs441 (ALDH2)
polymorphisms, controlling for sex, country and case–control status.
P-values associated with differences of heterozygous and homozygous
subjects compared with wild-type individuals were determined with Wald
tests, according to a w2-distribution with 1 d.f. In addition, the frequency of
subjects by category of alcohol consumption (low, medium and high) by
the three categories of each SNP were calculated.
The association between variants of SNPs and CRC risk was assessed by
odds ratio and corresponding 95% conﬁdence interval estimated in
conditional logistic regression models, in which the case–control set was
used as stratiﬁcation variable. For each SNP separately, keeping the wild-
type category consistently as the reference group, heterozygous and rare
homozygous categories were modelled with indicator variables. P-values
for statistical signiﬁcance of odds ratios for heterozygous and rare
ADH and ALDH gene polymorphisms and risk of colorectal cancer
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homozygous compared with wild-type individuals were obtained with
Wald test with 2 d.f. Adjustments by blood folate and alcohol intake, both
modelled as continuous variables, were performed, but results were not
meaningfully altered. Effect modiﬁcation by sex-speciﬁc categories
of alcohol intake at baseline (o5, 5–25, 425 g per day in women; o10,
10–50, 450 g per day in men), blood folate (EPIC-wide tertiles), sex and
country was assessed using indicator variables (as many as the number of
categories minus one), combining the heterozygous and rare homozygous
variants, and comparing log-likelihood of models with and without
interaction terms to a w2-distribution with degrees of freedom equal to
the number of interaction terms minus one. For the evaluation of potential
confounding and assessment of interaction with variants of SNPs, the total
number of CRC case–control sets used was 850, due to missing folate
measurement data. Potential differences in the associations by colon and
rectal cancer were explored in separate models.
All statistical analyses were performed using Stata Software.25 All tests
were two-tailed and statistical signiﬁcance was assessed at the 5% level.
RESULTS
The rs1229984 (ADH1B), rs1573496 (ADH7) and rs441 (ALDH2)
polymorphisms were in Hardy–Weinberg equilibrium in controls.
Baseline characteristics and description of the study population
are shown in Table 1. Total alcohol and beer intakes were
signiﬁcantly higher in cases than controls. For each polymorphism,
the frequency of study subjects by combination of genetic
categories and groups of alcohol intake are displayed in
Supplementary Table 1A. While frequencies of genetic variants
are rather constant across category of alcohol consumption for the
rs1573496 (ADH7) and rs441 (ALDH2) polymorphisms, the
percentage of subjects with low consumption (o5 and 10 g per
day in women and men, respectively) showed to be lower among
carriers of the ‘slow’ rs1229984(G) (ADH1B) allele (49%) than
subjects carrying one copy of the ‘fast’ rs1229984(A) allele (59%).
Consistently, opposite trends were observed among individuals
with elevated alcohol intake. In Table 2, means of total alcohol
intake and intakes of wine, beer and spirits are reported by
categories of SNP variants. Heterozygous subjects in the
rs1229984 (ADH1B) polymorphisms showed lower intakes of total
alcohol and wine intakes. The large mean values of total alcohol
and wine intakes displayed in rs1229984(A) (ADH1B) carriers are
largely explained by the limited sample size in this group (n¼ 12),
thus undermining the precision of these values. Other drinking
Table 1. Baseline characteristics of colorectal cancer cases and matched controls and country-specific cases and controls frequencies
Cases Matched controls
N 1269 2107
Age at recruitmenta 58.5±7.1 58.3±7.4
Men 621 1001
Women 648 1106
Smoking status
Non-smokers 533 (42%)
955 (45%)Smokers 421 (33%)
687 (33%)Ex-smokers 304 (24%)
445 (21%)Unknown 11 (1%)
9 (1%)
Physical activity
Inactive 310 (24%)
501 (24%)Moderately inactive 377 (30%)
622 (29%)Moderately active 260 (21%)
383 (18%)Active 232 (18%)
439 (21%)Unknown 90 (7%)
162 (8%)
% Meanc % Mean P-valued
Alcohol intake (g per day) 12.5 20.2 (0.8, 52.4) 14.5
17.4 (0.8, 45.5)
0.16
Wine 20.3 11.2 (0.2, 31.6) 22.9
10.9 (0.3, 31.6)
0.94
Beer 40.1 10.5 (0.2, 37.2) 44.7
7.8 (0.2, 21.2)
0.02
Spirits 43.6 3.3 (0.2, 7.5) 48.0
3.0 (0.2, 7.1)
0.20
Country (N)
France 33
59Italy 147
291Spain 121
236United Kingdom 216
398The Netherlands 150
287Greece 27
54Germany 157
303Sweden 76
131Denmark 337
339Norway 5
9
aMeans±s.d. bPercentage of study subjects who reported no consumption in the 12 months preceding the dietary questionnaire administration. cMeans
(10th, 90th percentiles) of total alcohol and alcoholic beverages intakes (g per day) in total alcohol- and beverage-specific non-zero consumers. dP-values for
(log-transformed) total alcohol intake and intakes of alcoholic beverages at baseline in relation to case–control status assessed with adjusted linear regression
models.
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levels according to variants of the rs1573496 (ADH7) and rs441
(ALDH2) SNPs were not clearly apparent.
Variants of rs1229984 (ADH1B), rs1573496 (ADH7) and rs441
(ALDH2) polymorphisms were overall not associated with color-
ectal, colon and rectal cancer risk (Table 3). Similarly to previous
ﬁndings in the EPIC cohort,26 in this study total alcohol intake was
associated with a signiﬁcant increase in the risk of colorectal,
colon and rectal cancer (results not shown). As reported in Table 4,
alcohol intake showed a more pronounced association with CRC
risk among subject carriers of the rare rs1573496(C) (ADH7) allele
(Pinteraction¼ 0.07), with odds ratio¼ 1.80 (95% conﬁdence interval:
1.02–3.17; P¼ 0.04) comparing high vs low alcohol intake among
heterozygous and wild-type homozygous subjects (estimates
obtained using a linear combination of model parameters).
No evidence of heterogeneity by blood folate (Pinteraction¼ 0.76,
0.69, 0.73 for rs1229984 (ADH1B), rs1573496 (ADH7), rs441 (ALDH2),
respectively), sex (Pinteraction¼ 0.90, 0.37, 0.90 for rs1229984 (ADH1B),
rs1573496 (ADH7), rs441 (ALDH2), respectively) or country
(Pinteraction¼ 0.79, 0.89, 0.26 for rs1229984 (ADH1B), rs1573496
(ADH7), rs441 (ALDH2), respectively) were apparent in the associa-
tions between each polymorphism and CRC risk (data not shown).
DISCUSSION
The results from this study nested within a European cohort
suggest that heterozygous subjects with the ‘fast’ rs1229984(A)
(ADH1B) allele have an average of 4.3 g per day lower alcohol
intake compared with homozygous participants, carrying two
Table 2. Number of subjects (% cases), means (s.d.) of intake of baseline intakea (g per day) of total alcohol, wine, beer and spirits, adjusted by sex,
country and case–control status, of total alcohol and wine intakes by variants of rs1229984 (ADH1B), rs1573496 (ADH7) and rs441 (ALDH2)
polymorphisms
N (%) Total alcohol Wine Beer Spirits
Mean (±s.e.) P-valueb Mean (±s.e.) P-valueb Mean (±s.e.) P-valueb Mean (±s.e.) P-valueb
rs1229984 (ADH1B)
G/G 2984 (38.3) 16.4±0.4 — 9.0±0.3 — 5.1±0.2 — 1.7±0.1 —
A/A 278 (36.0) 12.1±1.2 o0.01 5.4±0.9 o0.01 4.6±0.7 0.72 1.7±0.3 0.48
A/A 12 (41.7) 14.5±5.8 0.40 9.8±4.2 0.92 2.4±3.4 0.20 1.7±1.3 0.70
rs1573496 (ADH7)
G/G 2614 (37.3) 16.1±0.4 — 8.7±0.3 — 5.1±0.2 — 1.7±0.1 —
C/G 545 (38.3) 15.7±0.9 0.63 8.8±0.6 0.71 4.5±0.5 0.65 1.7±0.2 0.79
C/C 33 (39.4) 15.5±3.5 0.25 8.9±2.5 0.97 4.6±2.1 0.74 1.6±0.8 0.70
rs441 (ALDH2)
T/T 2153 (37.7) 15.9±0.4 — 8.7±0.3 — 5.0±0.3 — 1.7±0.5 —
T/C 997 (37.3) 16.1±0.6 0.84 8.6±0.5 0.96 5.0±0.4 0.23 1.7±0.5 0.25
C/C 103 (29.1) 16.1±2.0 0.59 8.3±1.4 0.58 5.9±1.2 0.62 1.4±0.5 0.22
aStudy subjects’ alcohol intake refers to the 12 months preceding the dietary questionnaire administration. bP-value associated with differences of log-
transformed total alcohol intake and intakes of alcoholic beverages at baseline for heterozygous and rare homozygous variants in relation to wild-type
individuals, assessed using adjusted linear regression models. For each genetic category, a Wald test was performed according to a w2-distribution with 1 d.f.
Table 3. Odds ratios (ORs) and 95% confidence interval (CI) for colorectal, rectum and colon cancer risk with rs1229984 (ADH1B), rs1573496 (ADH7)
and rs441 (ALDH2) polymorphisms
Variants Colorectal Rectum Colon
Case/control OR 95% CI Case/control OR 95% CI Case/control OR 95% CI
rs1229984 (ADH1B)
G/G 1129/1800 1 — 429/651 1 — 700/1149 1 —
G/A 97/176 0.95 0.72–1.24 30/66 0.77 0.48–1.21 67/110 1.07 0.77–1.49
A/A 5/6 1.36 0.41–4.53 2/— — — 3/6 0.86 0.21–3.50
P-valuea 0.81 0.52 0.89
rs1573496 (ADH7)
G/G 947/1549 1 — 337/543 1 — 610/1,006 1 —
C/G 205/311 1.09 0.90–1.32 79/110 1.17 0.85–1.61 126/201 1.04 0.81–1.32
C/C 13/19 1.30 0.64–2.64 6/5 2.73 0.78–9.57 7/14 0.87 0.35–2.18
P-valuea 0.55 0.19 0.91
rs441 (ALDH2)
T/T 794/1273 1 — 288/458 1 — 506/815 1 —
T/C 358/604 0.95 0.81–1.12 134/204 1.06 0.80–1.38 224/400 0.90 0.73–1.10
C/C 30/70 0.67 0.43–1.05 12/27 0.71 0.35–1.43 18/43 0.65 0.37–1.14
P-valuea 0.20 0.56 0.22
aP-value for difference in risk between heterozygous and rare homozygous compared with wild-type individuals, determined with a Wald test according to a
w2-distribution with 2 d.f.
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copies of the ‘slow’ rs1229984(G) (ADH1B). The reduction is mainly
attributable to lower wine intake, whereas the consumption of
beer and spirits are virtually unchanged in the two groups. No
clear differences in drinking levels were observed across variants
of the rs1573496 (ADH7) and rs441 (ALDH2) polymorphisms.
Subjects carrying copies of the fast alcohol metabolizer show a
tendency towards lower alcohol consumption, in line with
previous observations among Caucasian populations.27–30
The present study also shows that polymorphisms in the
rs1229984 (ADH1B), rs1573496 (ADH7) and rs441 (ALDH2) genes
are not associated with risk of CRC or of colon or of rectal cancers
in Caucasian populations. However, further analyses in the
rs1573496 (ADH7) polymorphism showed that alcohol intake
was associated with CRC risk among heterozygous and homo-
zygous carriers of the rare rs1573496(C) (ADH7) allele, while
among homozygous wild-type participants the alcohol CRC
association was weak. With respect to SNPs in the ALDH family,
similar genes alcohol interactions have been previously observed
for upper aero-digestive tract cancer,21 for head and neck
cancer,31 and for CRC.15
The alleles encoding the different ADH variants are hetero-
geneously distributed among ethnic groups.10 The allele
rs1229984(A) (ADH1B) codes for fast metabolism of ethanol,17
and is a major allele in Asian populations. In contrast, the allele
rs1229984(G) (ADH1B), which codes for slow metabolizer, is a
major allele in Caucasians.18 The frequency of subjects with two
copies of the rs1229984(G) (ADH1B) allele (‘slow’ metabolizer), of
the heterozygous subjects, and of the homozygous carrying two
rs1229984(A) (ADH1B) (‘fast’ metabolizer) was 90%, 9% and o1%
in our study, respectively, while it was around 5%, 35% and 60% in
studies conducted in Japan.16,19 This major difference in
frequency, that is, degree of genetic exposure, may explain the
inconsistency in risk estimates with respect to genetic factors as
the statistical power to detect an association will be greater in the
Japanese studies than ours.
The slow alcohol metabolizer of the rs1229984(G) (ADH1B)
polymorphism has been shown to be associated with various
alcohol-related conditions, such as an increased risk of alcoholic liver
disease,32 or cerebral infarction.33 For alcohol-related cancers, an
increased risk of upper aero-digestive tract cancers has been observed
consistently in studies conducted in Europe21,34 and in Japan.35
For CRC, no clear explanation for the increased risk associated
with the slow alcohol metabolizer rs1229984(G) (ADH1B) allele
observed in Asian populations15,16 has been provided. High
intracolonic acetaldehyde concentrations may result from
oxidation of ethanol by some strains of colonic bacteria, which
possesses ADH activity.8 This has been observed in vitro36 and
in vivo where acetaldehyde production was inhibited by antibiotic
treatment.37,38 Low activity of ALDH in colonic aerobic bacteria and
in mucosa may lead to acetaldehyde accumulation in the colon.8,39
This so called bacterio-colonic pathway of ethanol oxidation could
be a mechanism responsible for increased CRC risk associated with
elevated alcohol intake, in conjunction with a lack of link with
variants of the ADH genes, at least in Caucasian populations, where
limited genetic variability in the ADH family is observed. However,
testing this hypothesis is beyond the scope of the present work.
The association between alcohol and CRC risk has been
consistently observed in several epidemiological investiga-
tions,40–42 and in a pooled analysis of eight cohort studies.43
Similarly, in a full cohort analysis of the EPIC study lifetime alcohol
intake and alcohol intake at recruitment were positively associated
with the risk of CRC, the association being stronger for rectum
than for colon cancer.26 Similarly, in the present study alcohol
appeared to be positively associated with the risk of CRC (data not
shown).
Given drinking avoidance behaviour of 4.3 g per day associated
with rs1229984 (ADH1B) heterozygous subjects compared with
rs1229984(A) homozygous individuals in the present study,
relatively weak associations between alcohol-related SNPs and
risk of CRC are likely to be captured in this context. High alcohol
consumption may result in inadequate folate status by decreasing
intestinal absorption and increasing renal excretion.4 It is
hypothesized that low folate status increases the risk of CRC
by altering DNA methylation and DNA synthesis.44,45 It is known
that acetaldehyde, rather than alcohol itself, can cleave folate
chemically. A high intracolonic concentration of acetaldehyde
from bacterial production and metabolism of alcohol could thus
lead to decreased folate levels in the colonic mucosa. However,
the present study lacks the statistical power required to properly
evaluate how intake of dietary folate or blood folate levels may
modulate the CRC risk association between alcohol consumption
and ADH/ALDH genes.
To the best of our knowledge, this study is the largest study to
date conducted regarding the role of rs1229984 (ADH1B),
rs1573496 (ADH7) and rs441 (ALDH2) genes on CRC risk in
Caucasian populations. Our study conﬁrmed that the fast alcohol
metabolizer allele in the ADH1B polymorphism is associated
with a reduction of alcohol intake, mainly ascribable to wine
consumption, and that the rs1229984 (ADH1B) and rs441 (ALDH2)
polymorphisms showed no association with CRC risk. The
relationship between alcohol intake and risk of CRC seemed to
be modulated by the rs1573496(C) (ADH7) polymorphism.
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Table 4. Odds ratios and 95% confidence interval for colorectal cancer risk with rs1229984 (ADH1B), rs1573496 (ADH7) and rs441 (ALDH2)
polymorphisms by sex-specific categories of alcohol intake (g per day) at baseline
SNP Variants Total alcohol intakea
Low Medium High P-valueb Pinteraction
c
rs1229984 (ADH1B) G/G 1 (ref) 1.16 (0.97–1.37) 1.38 (1.07–1.79) 0.73
G/A, A/A 1.09 (0.77–1.54) 0.94 (0.61–1.49) 1.35 (0.59–3.09) 0.61 0.61
rs1573496 (ADH7) G/G 1 (ref) 1.20 (1.00–1.44) 1.21 (0.91–1.61) 0.12
G/C, C/C 1.18 (0.91–1.55) 1.02 (0.75–1.41) 2.13 (1.26–3.59) 0.04 0.07
rs441 (ALDH2) T/T 1 (ref) 1.21 (0.99–1.48) 1.43 (1.06–1.94) 0.03
T/C, C/C 1.02 (0.81–1.27) 0.94 (0.73–1.21) 1.48 (1.00–2.18) 0.10 0.25
aSex-specific categories of alcohol intake (g per day) were o5, 5–25, 425 in women, ando10, 10–50, and 450 in men, referring to study subjects’ intake
during the 12 months preceding dietary questionnaire administration. bP-value for difference in risk between high and medium compared with low alcohol
intake by categories of genetic variants, computed using Wald test for contrasts according to a w2-distribution with 2 d.f. cP-value for interaction between
categories of baseline alcohol intake (three categories) and variants of single-nucleotide polymorphisms (SNPs, two categories), comparing the log-likelihood
of models with and without interaction terms, according to a w2-distribution with 2 d.f.
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